Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
Rhea-AI Summary
Acurx Pharmaceuticals (Nasdaq: ACXP) announced that David P. Luci, President & Chief Executive Officer, will participate virtually in a fireside chat at the Alliance Global Partners Healthcare Company Showcase on Wednesday, May 24, 2025.
A replay will be available under the News / Events tab of the Acurx website at www.acurxpharma.com following the event.
Positive
- None.
Negative
- None.
News Market Reaction – ACXP
In the Apr 29 session, ACXP declined 4.37%, reflecting a moderate negative market reaction. Argus tracked a peak move of +12.2% during that session. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 27 | Investor conference | Neutral | +2.5% | Participation in the Market Movers Investor Summit presentation event. |
| Apr 20 | Earnings call notice | Neutral | -0.8% | Announcement of Q1 2026 results call and business update timing. |
| Apr 16 | Financing closed | Negative | -4.4% | Closing of registered direct offering and concurrent warrant placement. |
| Apr 16 | Financing announced | Negative | -19.7% | Announcement of up to $7.1M registered direct and warrant offering. |
| Mar 30 | Patent grant | Positive | -6.9% | Korean patent granted for DNA Polymerase IIIC inhibitors and ACX-375C program. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Equity offerings have coincided with negative price reactions, while neutral conference-type updates see mild moves. A notable divergence occurred when a positive Korean patent grant was followed by a share price decline.
Over the last month, Acurx has mixed news: conference participation, financing, and IP expansion. On Apr 16, 2026, a registered direct offering and concurrent warrants for up to $7.1 million aligned with sharp declines. Earlier, a Korean patent grant for DNA Polymerase IIIC inhibitors on Mar 30, 2026 was followed by a -6.91% move, diverging from the positive tenor. The current A.G.P. showcase appearance on Apr 29, 2026 fits the pattern of neutral, visibility-focused events.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A replay of the presentation will be available under the News / Events tab of the Acurx website following the event at www.acurxpharma.com.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).
Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection (CDI) is Phase 3 ready to advance to international clinical trials subject to obtaining appropriate financing. The Company recently announced the launch of a ground-breaking clinical trial with ibezapolstat in patients with multiply-recurrent CDI (rCDI) that has the potential to shift the paradigm of treatment and prevention of rCDI from two agents to one. This new clinical trial in rCDI begins with an open-label pilot trial to gain experience with IBZ in patients with multiply-recurrent CDI with at least 3 episodes of CDI within the past 12 months. This will inform elements of a planned active-controlled, Phase 3 registration trial in the rCDI indication to be implemented following favorable results from the open-label 20 patient trial. Upon subsequent successful completion of the Ph3 pivotal rCDI trial, and per the operative FDA procedure, Acurx plans to request FDA approval for treatment and prevention of rCDI under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (Guidance for Industry, 2020).
The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel.
To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.
Forward-Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the exercise of the short-term warrants prior to their expiration and the use of proceeds from the offering. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: market and other conditions, and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2025, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward-looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President & Chief Executive Officer
Tel: 917-533-1469
Email: davidluci@acurxpharma.co
View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-present-at-the-alliance-global-partners-agp-healthcare-company-showcase-302756793.html
SOURCE Acurx Pharmaceuticals, Inc.